BR9916477A - Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos - Google Patents

Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos

Info

Publication number
BR9916477A
BR9916477A BR9916477-9A BR9916477A BR9916477A BR 9916477 A BR9916477 A BR 9916477A BR 9916477 A BR9916477 A BR 9916477A BR 9916477 A BR9916477 A BR 9916477A
Authority
BR
Brazil
Prior art keywords
composition
polynucleotide
polynucleotides
vaccine
disclosed
Prior art date
Application number
BR9916477-9A
Other languages
English (en)
Inventor
Josee Hamel
Bernard R Brodeur
Clement Rioux
Isabelle Pineau
Denis Martin
Nathalie Charland
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9916477(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of BR9916477A publication Critical patent/BR9916477A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"POLINUCLETìDEO ISOLADO, POLINUCLEOTìDEO QUIMéRICO, COMPOSIçãO DE VACINA E USO DESTA COMPOSIçãO COMPREENDENDO OS POLINUCLEOTìDEOS". São reveladas proteínas de streptococcus e polinucleotídeos que a codificam. Tais proteínas são antigênicas e desta forma, componentes de vacina úteis para a profilaxia ou terapia de infecção por streptococcus em animais. Também são revelados métodos recombinantes de produção de antígenos de proteína, assim como ensaios de diagnóstico para detectar infecção bacteriana estreptocócica.
BR9916477-9A 1998-12-23 1999-12-20 Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos BR9916477A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23
PCT/CA1999/001218 WO2000039299A2 (en) 1998-12-23 1999-12-20 Streptococcus antigens

Publications (1)

Publication Number Publication Date
BR9916477A true BR9916477A (pt) 2004-06-22

Family

ID=22351610

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916477-9A BR9916477A (pt) 1998-12-23 1999-12-20 Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos

Country Status (30)

Country Link
EP (2) EP1141306B1 (pt)
JP (2) JP4761623B2 (pt)
KR (4) KR101078919B1 (pt)
CN (3) CN100398653C (pt)
AP (1) AP2001002199A0 (pt)
AR (1) AR029322A1 (pt)
AT (1) ATE394489T1 (pt)
AU (1) AU1764900A (pt)
BR (1) BR9916477A (pt)
CA (1) CA2356836C (pt)
CL (1) CL2009002037A1 (pt)
CY (3) CY1108223T1 (pt)
CZ (2) CZ303675B6 (pt)
DE (1) DE69938670D1 (pt)
DK (3) DK1950302T3 (pt)
EA (1) EA007409B1 (pt)
ES (3) ES2400280T3 (pt)
HK (1) HK1118575A1 (pt)
HU (1) HU229664B1 (pt)
IL (3) IL143905A0 (pt)
MX (1) MXPA01006427A (pt)
NO (1) NO330800B1 (pt)
NZ (1) NZ512574A (pt)
OA (1) OA11736A (pt)
PL (3) PL206576B1 (pt)
PT (3) PT1141306E (pt)
TR (2) TR200102497T2 (pt)
UY (1) UY25877A1 (pt)
WO (1) WO2000039299A2 (pt)
ZA (1) ZA200105114B (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2505999A (en) 1998-02-20 1999-09-06 Biochem Pharma Inc. Group b streptococcus antigens
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
EP2050464B1 (en) 1998-12-21 2019-08-07 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
HU229664B1 (en) * 1998-12-23 2014-04-28 Id Biomedical Corp Quebec Streptococcus antigens
WO2001096379A2 (en) 2000-06-12 2001-12-20 University Of Saskatchewan Immunization of dairy cattle with chimeric gapc protein against streptococcus infection
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
EP1303612A2 (en) 2000-06-20 2003-04-23 Shire Biochem Inc. Streptococcus antigens
AU2002242549A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
WO2003004650A2 (en) * 2001-07-06 2003-01-16 Shire Biochem Inc. Group b streptococcus antigens and corresponding dna fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
AU2002351623A1 (en) * 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
SI1601770T1 (sl) 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
EP2314718A1 (en) 2003-04-15 2011-04-27 Intercell AG S. pneumoniae antigens
NZ569076A (en) 2005-12-22 2011-08-26 Glaxosmithkline Biolog Sa Vaccine comprising capsular polysaccharides conjugates from Streptococcus pneumoniae serotypes 19A and 19F
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
DK2167121T3 (en) 2007-06-26 2015-11-23 Glaxosmithkline Biolog Sa A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater
WO2009012588A1 (en) * 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
CA2720961A1 (en) * 2008-04-16 2009-10-22 William Ripley Ballou, Jr. Streptococcus pneumonia vaccine
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
US20120052088A1 (en) 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
RU2538162C2 (ru) 2009-09-03 2015-01-10 Пфайзер Вэксинс ЭлЭлСи Вакцина против pcsk9
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
AU2012207088A1 (en) * 2011-01-20 2013-05-02 Children's Medical Center Corporation Vaccines and compositions against Streptococcus pneumoniae
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
BR112013029514A2 (pt) 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, método de tratar ou impedir uma doença
MX349494B (es) * 2012-01-05 2017-08-01 Deutsches Krebsforsch Medios y metodos para tratar o diagnosticar canceres positivos a idh1 r132h mutante.
WO2014089706A1 (en) * 2012-12-14 2014-06-19 Sanofi Pasteur, Ltd. Methods for assessing immunogenicity
PT3096783T (pt) 2014-01-21 2021-08-16 Pfizer Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2820824T3 (es) 2014-01-21 2021-04-22 Pfizer Composiciones inmunogénicas que comprenden antígenos sacáridos capsulares conjugados y usos de las mismas
RU2688831C2 (ru) 2014-01-21 2019-05-22 Пфайзер Инк. Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты
ES2701169T3 (es) 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
US10653764B2 (en) 2015-01-15 2020-05-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
MX2018000867A (es) 2015-07-21 2018-05-15 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos.
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3570879B1 (en) 2017-01-20 2022-03-30 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN114728050A (zh) 2019-07-31 2022-07-08 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
IL292494A (en) 2019-11-01 2022-06-01 Pfizer Preparations of Escherichia coli and their methods
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
EP4333879A1 (en) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220387613A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
CA2158658A1 (en) * 1993-03-19 1994-09-29 Margaretha Stalhammar-Carlemalm Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition
AP9701163A0 (en) * 1995-06-07 1998-01-31 Biochem Vaccines Inc Streptococcal heat shock proteins members of the HSP70 family.
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
EP1400592A1 (en) 1996-10-31 2004-03-24 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
CA2305016A1 (en) * 1997-09-24 1999-04-01 Regents Of The University Of Minnesota Human complement c3-degrading proteinase from streptococcus pneumoniae
AU770378B2 (en) * 1998-04-23 2004-02-19 Uab Research Foundation Pneumococcal surface protein C(PspC), epitopic regions and strain selection thereof, and uses therefor
ATE361365T1 (de) * 1998-07-27 2007-05-15 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
CN1318103A (zh) * 1998-07-27 2001-10-17 微生物技术有限公司 肺炎链球菌的核酸和蛋白质
IL142017A0 (en) * 1998-09-24 2002-03-10 Univ Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
EP2050464B1 (en) * 1998-12-21 2019-08-07 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
HU229664B1 (en) * 1998-12-23 2014-04-28 Id Biomedical Corp Quebec Streptococcus antigens

Also Published As

Publication number Publication date
NO20013045L (no) 2001-08-20
CN1191362C (zh) 2005-03-02
CN100398653C (zh) 2008-07-02
CA2356836C (en) 2011-09-13
KR101078919B1 (ko) 2011-11-01
KR20060134227A (ko) 2006-12-27
IL143905A (en) 2011-05-31
PT1141306E (pt) 2008-07-30
MXPA01006427A (es) 2002-06-04
EP2261358A2 (en) 2010-12-15
NO20013045D0 (no) 2001-06-19
HU229664B1 (en) 2014-04-28
PL206576B1 (pl) 2010-08-31
ES2306528T3 (es) 2008-11-01
PL349777A1 (en) 2002-09-09
ES2480417T3 (es) 2014-07-28
TR200102497T2 (tr) 2002-01-21
DK1950302T3 (da) 2013-01-14
CN101134775A (zh) 2008-03-05
NZ512574A (en) 2004-03-26
CY1115340T1 (el) 2017-01-04
CN1332803A (zh) 2002-01-23
AP2001002199A0 (en) 2001-09-30
KR101170203B1 (ko) 2012-07-31
DK2261358T3 (da) 2014-07-28
ATE394489T1 (de) 2008-05-15
CA2356836A1 (en) 2000-07-06
HUP0104774A2 (hu) 2002-04-29
KR20010104693A (ko) 2001-11-26
JP4761623B2 (ja) 2011-08-31
KR100891398B1 (ko) 2009-04-02
KR20100063814A (ko) 2010-06-11
CL2009002037A1 (es) 2010-06-25
IL194230A0 (en) 2011-08-01
EP1141306A2 (en) 2001-10-10
EP2261358B1 (en) 2014-05-14
DE69938670D1 (de) 2008-06-19
CN1654657A (zh) 2005-08-17
IL194230A (en) 2013-12-31
JP2010142246A (ja) 2010-07-01
EA007409B1 (ru) 2006-10-27
OA11736A (en) 2005-06-12
CY1108223T1 (el) 2014-02-12
AR029322A1 (es) 2003-06-25
PT2261358E (pt) 2014-07-30
EP1141306B1 (en) 2008-05-07
KR100802198B1 (ko) 2008-02-11
JP2002533123A (ja) 2002-10-08
PL205041B1 (pl) 2010-03-31
CZ20012161A3 (cs) 2001-10-17
PL204073B1 (pl) 2009-12-31
HK1118575A1 (en) 2009-02-13
ES2400280T3 (es) 2013-04-08
WO2000039299A3 (en) 2000-11-02
ZA200105114B (en) 2002-11-21
CY1114722T1 (el) 2016-10-05
TR200200633T2 (tr) 2002-06-21
CZ302790B6 (cs) 2011-11-09
HUP0104774A3 (en) 2007-10-29
NO330800B1 (no) 2011-07-18
JP5039802B2 (ja) 2012-10-03
CZ303675B6 (cs) 2013-02-27
IL143905A0 (en) 2002-04-21
AU1764900A (en) 2000-07-31
EA200100565A1 (ru) 2002-04-25
DK1141306T3 (da) 2008-08-18
UY25877A1 (es) 2000-08-21
KR20080036666A (ko) 2008-04-28
PT1950302E (pt) 2013-01-16
WO2000039299A2 (en) 2000-07-06
EP2261358A3 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
BR9916477A (pt) Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos
MXPA03000103A (es) Antigenos de streptococcus.
AP2000001886A0 (en) Group B streptococcus antigens.
BR0015137A (pt) Peptìdeos antigênicos de neisseria
BR0208944A (pt) quadros de leitura aberta de streptococus pneumoniae codificando os antìgenos de polipeptìdeos e seus usos
ATE479756T1 (de) Streptococcus pneumoniae-antigene und impfstoffe
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
AR003124A1 (es) Proteinas estreptococicas de shock termico miembros de la familia de hsp7270,secuencia de adn que codifica para dichos polipeptidos, vector deexpresion, molecula de adn recombinante, metodo para producir un polipeptido o fragmento del mismo, anticuerpo o fragmento del mismo y anticuerpo monoclonal,
ATE382055T1 (de) Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren
WO2000005378A3 (en) Streptococcus suis vaccines and diagnostic tests
NO20011381L (no) Preparater av streptokokk C<beta>-protein
FR2766193B1 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
BR0108654A (pt) Composição imunogênica, polipeptìdeo isolado, vetor de expressão ou um microorganismo vivo recombinante, célula hospedeira, processos para produzir uma composição imunogênica e um polipeptìdeo ou um fragmento imunogênico do mesmo, uso de um polipeptìdeo ou de um polinucleotìdeo que codifica um polipeptìdeo, método para o tratamento de um indivìduo pela imunoprofilaxia ou terapia, anticorpo, agonista ou antagonista ao polipeptìdeo, composto, e, processos para diagnosticar, uma doença ou uma suscetibilidade a uma doença e a presença de câncer colorretal ou uma suscetibilidade ao câncer colorretal, em um indivìduo
WO2002057315A3 (en) Streptococcal streptolysin s vaccines
PT917471E (pt) Tratamento e diagnostico de infeccoes por cocci gram-positivo
BR9908476A (pt) Peptìdeo, composição terapêutica, e, processo para conferir imunidade protetora a um paciente, contra a infecção de s. pneumoniae
MX9805158A (es) Adn que codifica una proteina activadora de plasminogeno.
WO2002030977A3 (en) Egf motif protein, egfl6 materials and methods
BR0111886A (pt) Antìgeno para estreptococos
DE69033553D1 (de) Rekombinante herstellung von laktoperoxidase
BR0012740A (pt) Compostos para tratamento de distúrbios do sistema infeccioso e imune e métodos para seu emprego
EP1950302A3 (en) Streptococcus antigens
EP1219635A3 (en) Chlamydia pneumoniae antigenes
ATE341613T1 (de) Fluordesoxyuridin-resistente streptococcus gordonii stämme

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ID BIOMEDICAL CORPORATION (CA)

Free format text: TRANSFERIDO DE: SHIRE BIOCHEM INC.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO DE TRANSFERENCIA E ALTERACAO DE SEDE NO 020050112625/RJ DE 11/10/2005, POIS TAL ATO JA FOI DEFERIDO E PUBLICADO NA RPI 1849 DE 13/06/2006.

B25G Requested change of headquarter approved

Owner name: ID BIOMEDICAL CORPORATION (CA)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070101374/RJ DE 24/07/2007.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (IX), 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O MESMO DEVERA APRESENTAR DECLARACAO CONFORME ARTO 10 DA RESOLUCAO 81/2013 DE 28/03/2013.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULADA A EXIGENCIA PUBLICADA NA RPI 2254 DE 18/03/2014, POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time